Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Pharmacology

Background:

• COVID-19-associated acute respiratory distress syndrome (ARDS) poses a significant mortality risk.
• Janus kinase (JAK) inhibitors, like ruxolitinib, have been investigated for their immunomodulatory effects in severe inflammatory conditions.

Purpose of the Study:

• To evaluate the safety and efficacy of ruxolitinib in mechanically ventilated patients with COVID-19-associated ARDS.
• To assess the impact of ruxolitinib on 28-day mortality and other clinical outcomes.

Main Methods:

• A Phase 3, randomized, double-blind, placebo-controlled trial (RUXCOVID-DEVENT) involving 211 mechanically ventilated patients with COVID-19-associated ARDS.
• Patients received either ruxolitinib (15 mg or 5 mg twice daily) or placebo, in addition to standard care.
• The primary endpoint was 28-day mortality, analyzed using mixed-effects logistic regression.

Main Results:

• 28-day mortality was 51% for ruxolitinib 15 mg, 53% for ruxolitinib 5 mg, and 70% for placebo.
• Neither ruxolitinib dose significantly reduced 28-day mortality compared to placebo (p=0.029 and p=0.028, respectively).
• Ruxolitinib 15 mg showed numerical improvements in ventilator-free, ICU-free, and vasopressor-free days; adverse event rates were similar across groups.

Conclusions:

• Ruxolitinib did not achieve statistical significance in reducing 28-day mortality in this patient population.
• The trial was underpowered due to early termination, limiting definitive conclusions.
• Further research may be warranted, considering the observed trends in secondary outcomes and safety profile.